Ben Cosgrove: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
No edit summary
No edit summary
 
(15 intermediate revisions by the same user not shown)
Line 6: Line 6:
[[Image:Ben_Cosgrove.jpg|200px|right]]
[[Image:Ben_Cosgrove.jpg|200px|right]]


'''Ben Cosgrove''' [http://web.mit.edu/bcosgrov/www/bdc_cv.pdf CV] [mailto:bcosgrov@mit.edu email] [http://www.epernicus.com/users/338 Epernicus]
'''Ben Cosgrove''' [http://www.stanford.edu/~cosgrove/cosgrove_cv.pdf CV] [mailto:cosgrove@stanford.edu email] [http://www.epernicus.com/bc Epernicus]


Ph.D. Student
Ph.D., Bioengineering, Department of Biological Engineering, M.I.T.


Biological Engineering Division [http://web.mit.edu/be/index.htm webpage]


Massachusetts Institute of Technology [http://web.mit.edu webpage]
''Current affiliation:''


Postdoctoral Fellow, Molecular Imaging Program at Stanford, Stanford University School of Medicine


''Research Advisors:''
 
''Ph.D. Research Advisors:''


* Linda Griffith [http://web.mit.edu/lgglab/ webpage]
* Linda Griffith [http://web.mit.edu/lgglab/ webpage]
Line 21: Line 22:




''Research Summary:''
''Ph.D. Research Summary:''


"Quantitative Analysis of Cytokine-Induced Hepatocyte Proliferation, Apoptosis, and Toxicity"
"Quantitative Analysis of Cytokine-Induced Hepatocyte Proliferation, Apoptosis, and Toxicity"


Many therapeutic agents, including viral gene therapy vectors and small molecule pharmaceutical compounds, are confounded by liver toxicity due to, in part, relationships with inflammatory stimuli in eliciting hepatocyte toxicity and/or death.  Our work focuses on developing physiologically relevant in vitro approaches to quantitatively assess how hepatocytes regulate, through the activities of intracellular and extracellular signaling networks, cell fate decisions related to proliferation, survival, apoptosis, and differentiated function following cytokine stimulation in the presence of viral gene therapy agents or small molecule drugs.   
Many therapeutic approaches, including viral gene therapy agents and small molecule pharmaceutical compounds, are confounded by liver toxicity due to, in part, synergistic relationships with inflammatory stimuli in eliciting hepatocyte toxicity and/or death.  My work focuses quantitatively measuring and modeling how hepatocytes regulate, through the activities of intracellular and extracellular signaling networks, cell behavioral responses following cytokine stimulation in the presence of viral gene therapy agents or small molecule drugs in physiologically relevant ''in vitro'' cell models.
 
Initially, I examined the role of the inflammatory cytokine tumor necrosis factor-α (TNF), which regulates both hepatocyte proliferation and apoptosis ''in vivo''I showed that TNF stimulates hepatocyte proliferation and (adenoviral vector infection-sensitized) apoptosis ''in vitro'' through a time-varying autocrine cascade involving the growth factor TGF-α and the cytokines IL-1α/β and IL-1ra. I demonstrated that the inducible TGF-α–IL-1α/β–IL-1ra autocrine cascade regulates hepatocyte responses to TNF in a self-antagonizing manner by modulating multiple signaling pathways, including Akt, ERK, JNK, p38, and IKK–NF-κB, downstream of TNFR that both positively and negatively regulate hepatocyte proliferation and apoptosis.
 
Currently, I am developing ''in vitro'' models of idiosyncratic drug hepatotoxicity by examining the interactions between multiple pharmaceutical compounds and inflammatory cytokines. In this work, I aim to elucidate how certain idiosyncratic hepatotoxic drugs exhibit synergistic toxicity relationships with inflammatory cytokines by collecting systems-level intracellular signaling data and phenotypic cellular toxicity data. This data set has been used to develop data-driven signaling-outcome models through partial least squares regression (PLSR) approaches to identify and predict key signaling activities that regulate a diverse set of hepatocyte toxicity phenotypes and to inform future therapeutic strategies.
 
 
''Publications:''
 
[1] Cosgrove BD, Griffith LG, Lauffenburger DA. Fusing tissue engineering and systems biology toward fulfilling their promise. ''Cellular and Molecular Bioengineering'' 1:33-41, 2008. [http://dx.doi.org/10.1007/s12195-008-0007-9 DOI].
 
[2] Cosgrove BD, Cheng C, Pritchard JR, Stolz DB, Lauffenburger DA, Griffith LG. An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor-α. ''Hepatology'' 48(1):276-288, 2008. [http://dx.doi.org/10.1002/hep.22335 DOI].
 


Initially, we examined the role of a specific inflammatory cytokine, tumor necrosis factor alpha (TNF), which regulates both hepatocyte proliferation and apoptosis in vivo.  We have shown that TNF stimulates hepatocyte proliferation in vitro through a contingent, inducible autocrine cascade containing the growth factor TGF-alpha and the cytokines IL-1alpha/beta.  This TGF-alpha-IL-1 autocrine cascade regulates TNF-induced hepatocyte proliferation in a self-limiting manner as TGF-alpha positively regulates proliferation while also upregulating autocrine IL-1 release, which negatively regulates proliferation.  Similarly, we have shown that TNF potently stimulates apoptosis in hepatocytes infected with a replication-deficient adenovirus in vitro as mediated by the same TGF-alpha-IL-1 autocrine cascade. 
''Honors:''


Currently, we are developing in vitro models of idiosyncratic drug hepatotoxicity by examining the interactions between multiple pharmaceutical compounds and inflammatory cytokines.  In this work, we aim to elucidate how certain idiosyncratic hepatotoxic drugs exhibit synergistic toxicity relationships with inflammatory cytokines by collecting systems-level intracellular signaling data (using multiplexed kinase activity assays and bead-based phosphoprotein detection schemes) and phenotypic cell response data (using imaging-based assays of differentiated function and high-throughput cell necrosis and apoptosis assays).  This data set will be used to develop statistical signaling-outcome models through partial least squares regression (PLSR) approaches to identify and predict key signaling activities that regulate a diverse set of hepatocyte toxicity phenotypes and to inform future therapeutic strategies.
* ''2008'' Ben Trump Award, Aspen Cancer Conference
* ''2008'' Graduate Student Research Award, Biomedical Engineering Society
* ''2003-2006'' Whitaker Foundation Graduate Fellowship in Biomedical Engineering
* ''1999-2003'' National Merit Scholarship




Line 35: Line 51:
* MIT Biotechnology Process Engineering center [http://web.mit.edu/bpec/ webpage]
* MIT Biotechnology Process Engineering center [http://web.mit.edu/bpec/ webpage]
* MIT Center for Cell Decision Processes [http://cdp.mit.edu/ webpage] [http://cdpwiki.mit.edu/ internal wiki]
* MIT Center for Cell Decision Processes [http://cdp.mit.edu/ webpage] [http://cdpwiki.mit.edu/ internal wiki]
* MIT Center for Cancer Research [http://web.mit.edu/ccr/ webpage]





Latest revision as of 12:19, 17 February 2009

Home        People        Research        Publications        Links        Internal       

Ben Cosgrove CV email Epernicus

Ph.D., Bioengineering, Department of Biological Engineering, M.I.T.


Current affiliation:

Postdoctoral Fellow, Molecular Imaging Program at Stanford, Stanford University School of Medicine


Ph.D. Research Advisors:


Ph.D. Research Summary:

"Quantitative Analysis of Cytokine-Induced Hepatocyte Proliferation, Apoptosis, and Toxicity"

Many therapeutic approaches, including viral gene therapy agents and small molecule pharmaceutical compounds, are confounded by liver toxicity due to, in part, synergistic relationships with inflammatory stimuli in eliciting hepatocyte toxicity and/or death. My work focuses quantitatively measuring and modeling how hepatocytes regulate, through the activities of intracellular and extracellular signaling networks, cell behavioral responses following cytokine stimulation in the presence of viral gene therapy agents or small molecule drugs in physiologically relevant in vitro cell models.

Initially, I examined the role of the inflammatory cytokine tumor necrosis factor-α (TNF), which regulates both hepatocyte proliferation and apoptosis in vivo. I showed that TNF stimulates hepatocyte proliferation and (adenoviral vector infection-sensitized) apoptosis in vitro through a time-varying autocrine cascade involving the growth factor TGF-α and the cytokines IL-1α/β and IL-1ra. I demonstrated that the inducible TGF-α–IL-1α/β–IL-1ra autocrine cascade regulates hepatocyte responses to TNF in a self-antagonizing manner by modulating multiple signaling pathways, including Akt, ERK, JNK, p38, and IKK–NF-κB, downstream of TNFR that both positively and negatively regulate hepatocyte proliferation and apoptosis.

Currently, I am developing in vitro models of idiosyncratic drug hepatotoxicity by examining the interactions between multiple pharmaceutical compounds and inflammatory cytokines. In this work, I aim to elucidate how certain idiosyncratic hepatotoxic drugs exhibit synergistic toxicity relationships with inflammatory cytokines by collecting systems-level intracellular signaling data and phenotypic cellular toxicity data. This data set has been used to develop data-driven signaling-outcome models through partial least squares regression (PLSR) approaches to identify and predict key signaling activities that regulate a diverse set of hepatocyte toxicity phenotypes and to inform future therapeutic strategies.


Publications:

[1] Cosgrove BD, Griffith LG, Lauffenburger DA. Fusing tissue engineering and systems biology toward fulfilling their promise. Cellular and Molecular Bioengineering 1:33-41, 2008. DOI.

[2] Cosgrove BD, Cheng C, Pritchard JR, Stolz DB, Lauffenburger DA, Griffith LG. An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor-α. Hepatology 48(1):276-288, 2008. DOI.


Honors:

  • 2008 Ben Trump Award, Aspen Cancer Conference
  • 2008 Graduate Student Research Award, Biomedical Engineering Society
  • 2003-2006 Whitaker Foundation Graduate Fellowship in Biomedical Engineering
  • 1999-2003 National Merit Scholarship


Member of:


Funding: